# EDGAR Filing Document

**Accession Number:** 0001782223
**File Stem:** 0001193125-26-194051
**Filing Date:** 2026-4
**Character Count:** 5012
**Document Hash:** cd77d0afaaa42ac4f4cc58acf97e4068
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-194051.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001193125-26-194051

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pyxis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001782223
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831160910
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40881
- **FILM NUMBER:** 26920119

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** (617) 221-9059

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**SCHEDULE 14A**

**(Rule 14a-101)**

**INFORMATION REQUIRED IN PROXY STATEMENT**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

---

| | |
|:---|:---|
| 5 ☐ | Preliminary Proxy Statement |
| ☐ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |

---

---

| |
|:---|
| **PYXIS ONCOLOGY, INC.**<br>**(Name of Registrant as Specified in its Charter)** |
| **(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)** |

---

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

![img53096847_0.jpg](img53096847_0.jpg)

------

PYXIS ONCOLOGY P.O. Box 8016, CARY, NC 27512-9903 YOUR VOTE MATTERS! Scan QR for digital voting Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2024 For stockholders of record as of April 18, 2024 To order paper materials, use one of the following methods. INTERNET: www.investorelections.com/ Call 1-866-648-8133 paper@investorelections.com \* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Pyxis Oncology, Inc. Annual Meeting of Stockholders Tuesday, June 11, 2024 10:00 AM, Eastern Time Annual Meeting to be held live via the internet - please visit at www.proxydocs.com/PYXS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/PYXS For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/PYXS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 31, 2024. SEE REVERSE FOR FULL AGENDA Copyright© 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved

![img53096847_1.jpg](img53096847_1.jpg)

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 Pyxis Oncology, Inc. Annual Meeting of Stockholders 1. The election of one Class I director and three Class III directors named in the proxy statement 1.01 Santhosh Palani, Ph.D., CFA 1.02 John Flavin 1.03 Lara Sullivan,M.D. 1.04 Jakob Dupont,M.D. 2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 NOTE: The transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof.

------